

Substitute for form 1449A/PTO  
(Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

## Complete if Known

Application Number 10/611,399  
Filing Date July 1, 2003  
First Named Inventor DESJARLAIS et al.  
Art Unit 1646  
Examiner Name To Be Assigned  
Attorney Docket Number A-71273-3/RMS/RMK

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
[Signature]	A1	5,556,786	09-17-1996	Kere et al.	
	A2	5,573,924	11-12-1996	Beckmann et al.	
	A3	5,700,926	12-23-1997	Kere et al.	
	A4	6,017,729	01-25-2000	Anderson et al.	
	A5 *	6,188,965 B1	02-13-2001	Mayo et al.	
	A6 *	6,269,312 B1	07-31-2001	Mayo et al.	
	A7	6,316,408 B1	11-13-2001	Boyle	
	A8	6,355,782 B1	03-12-2002	Zonana et al.	
	A9 *	6,403,312 B1	06-11-2002	Dahiyat et al.	
	A10 *	6,708,120 B1	03-16-2004	Mayo et al.	
	A11 *	2001/0032052 A1	10-18-2001	Mayo et al.	
	A12 *	2001/0039480 A1	11-08-2001	Mayo et al.	
	A13 *	2002/0004706 A1	01-10-2002	Mayo et al.	
	A14 *	2002/0009780 A1	01-24-2002	Dahiyat et al.	
	A15 *	2002/0048772 A1	04-25-2002	Dahiyat et al.	
	A16	2002/0064527 A1	05-30-2002	Mohler et al.	
	A17 *	2002/0090648 A1	07-11-2002	Dahiyat et al.	
	A18 *	2002/0106694 A1	08-08-2002	Mayo et al.	
	A19 *	2002/0110868 A1	08-15-2002	Dahiyat et al.	
	A20 *	2003/0049654 A1	03-13-2003	Dahiyat et al.	
	A21 *	2003/0130827 A1	07-10-2003	Bentzien et al.	
	A22 *	2003/0138401 A1	07-24-2003	Dahiyat et al.	
	A23 *	2003/0166559 A1	09-04-2003	Desjarlais et al.	
	A24 *	2003/0219864 A1	11-27-2003	Desjarlais et al.	
	A25 *	2004/0043429 A1	03-04-2004	Dahiyat et al.	
	A26 *	2004/0043430 A1	03-04-2004	Dahiyat et al.	
	A27 *	2004/0121363 A1	06-24-2004	Desjarlais et al.	
	A28 *	2004/0170602 A1	09-02-2004	Desjarlais et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
--------------------	-----------------------	---	-----------------------------	---	---	----------------

Examiner Signature	[Signature]	Date Considered	4/6/2006
--------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/611,399	
			Filing Date	July 1, 2003	
			First Named Inventor	DESJARLAIS et al.	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	2	of	8	Attorney Docket Number	A-71273-3/RMS/RMK

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
[Signature]	B1 *	EP 0 974 111 B1	01-26-2000	California Institute of Technology		
	B2	WO 98/24895 A1	06-11-1998	Pharmacia & Upjohn		
	B3 *	WO 98/47089 A1	10-22-1998	California Institute of Technology		
	B4 *	WO 00/23564 A2	04-27-2000	Xencor, Inc.		
	B5	WO 00/49149 A1	08-24-2000	Kitamura	English Abstract	
	B6 *	WO 01/59066 A2, A3	08-16-2001	Xencor, Inc.		
	B7	WO 02/02641 A1	01-10-2002	Human Genome Sciences		
	B8	WO 02/092620 A2	11-21-2002	Amgen		
	B9 *	WO 03/014325 A2, A3	02-20-2003	Xencor		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T*
X L A T E  ↓	C1	AGGARWAL, BB et al., "TNF Receptors," in Cytokine Reference, Oppenheim et al. Eds., Academic Press 2000, pp. 1619-1632		
	C2	ANDRE P, et al., "Platelet-derived CD40L: the switch-hitting player of cardiovascular disease." Circulation. 2002 Aug 20;106(8):896-9.		
	C3	ASHKENAZI A, et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand." J Clin Invest. 1999 Jul;104(2):155-62.		
	C4	BARNES PJ. "Cytokine modulators as novel therapies for asthma." Annu Rev Pharmacol Toxicol. 2002;42:81-98.		
	C5	BODMER JL, et al., "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem. 2000 Jul 7;275(27):20632-7.		
	C6	BODMER JL, et al., "The molecular architecture of the TNF superfamily." Trends Biochem Sci. 2002 Jan;27(1):19-26.		
	C7	BOWMAN MR, et al., "The cloning of CD70 and its identification as the ligand for CD27." J Immunol. 1994 Feb 15;152(4):1756-61.		
	C8	CAPPELLO P, et al., "Death receptor ligands in tumors." J Immunother. 2002 Jan-Feb;25(1):1-15.		
	C9	CHA SS, et al., "2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity." Immunity. 1999 Aug;11(2):253-61.		
	C10	CHAN KF, et al., "Signaling by the TNF receptor superfamily and T cell homeostasis." Immunity. 2000 Oct;13(4):419-22.		
	C11	CHESS, L, "Blockade of the CD40L/CD40 Pathway," in Therapeutic Immunology 2nd, Austen, K.F. et al. Eds. Blackwell Sciences 2001 pp. 441-456		

Examiner Signature	[Signature]	Date Considered	7/6/2006
--------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 †Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*\*\* Applicant is to place a check mark here if English Language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449/APTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/611,399
				Filing Date	July 1, 2003
				First Named Inventor	DESJARLAIS et al.
				Art Unit	1646
				Examiner Name	To Be Assigned
				Attorney Docket Number	A-71273-3/RMS/RMK
Sheet	3	of	8		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
✓	C12	CHICHEPORTICHE Y, et al., "Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies." Arthritis Res. 2002;4(2):126-33.	
	C13	CHICHEPORTICHE Y, et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis." J Biol Chem. 1997 Dec 19;272(51):32401-10.	
	C14	CRETNEY E, et al., "Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice." J Immunol. 2002 Feb 1;168(3):1356-61.	
	C15	CROW MK, et al., "Regulation of CD40 ligand expression in systemic lupus erythematosus." Curr Opin Rheumatol. 2001 Sep;13(5):361-9.	
	C16	DEGLI-ESPOSTI MA, et al., "The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain." Immunity. 1997 Dec;7(6):813-20.	
	C17	DO RK, et al., "Mechanism of BLyS action in B cell immunity." Cytokine Growth Factor Rev. 2002 Feb;13(1):19-25.	
	C18	EL-DEIRY WS. "Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling." Cell Death Differ. 2001 Nov;8(11):1066-75.	
	C19	EMERY JG, et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL." J Biol Chem. 1998 Jun 5;273(23):14363-7.	
	C20	FELDMANN M, et al., "Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?" Annu Rev Immunol. 2001;19:163-96.	
	C21	FELDMANN M, et al., "Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies." Joint Bone Spine. 2002 Jan;69(1):12-8.	
	C22	GOATER JJ, et al., "Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis." J Orthop Res. 2002 Mar;20(2):169-73.	
	C23	GREWAL IS, et al., "CD40 and CD154 in cell-mediated immunity." Annu Rev Immunol. 1998;16:111-35.	
	C24	GRIFFITH TS, et al., "Functional analysis of TRAIL receptors using monoclonal antibodies." J Immunol. 1999 Mar 1;162(5):2597-605.	
	C25	GROOM J, et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome." J Clin Invest. 2002 Jan;109(1):59-68.	
	C26	GURNEY AL, et al., "Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR." Curr Biol. 1999 Feb 25;9(4):215-8.	
	C27	HANNINEN A, et al., "Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity." J Clin Invest. 2002 Jan;109(2):261-7.	
	C28	HARIDAS V, et al., "VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth." Oncogene. 1999 Nov 11;18(47):6496-504.	
	C29	HARROP JA, et al., "Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth." J Biol Chem. 1998 Oct 16;273(42):27548-56.	
	C30	HEADON DJ, et al., "Gene defect in ectodermal dysplasia implicates a death domain adapter in development." Nature. 2001 Dec 20-27;414(6866):913-6.	
	C31	HELDIN CH. "Dimerization of cell surface receptors in signal transduction." Cell. 1995 Jan 27;80(2):213-23.	
✓	C32	HINTZEN RQ, et al., "Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation." J Immunol. 1995 Mar 15;154(6):2612-23.	

Examiner Signature <i>Helgon Kim</i>	Date Considered	4/6/2006
--------------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/611,399
				Filing Date	July 1, 2003
				First Named Inventor	DESJARLAIS et al.
				Art Unit	1646
				Examiner Name	To Be Assigned
				Attorney Docket Number	A-71273-3/RMS/RMK
Sheet	4	of	8		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C33	HOFBAUER LC, et al., "Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases." Cancer. 2001 Aug 1;92(3):460-70.		
	C34	HOLLENBAUGH D, et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity." EMBO J. 1992 Dec;11(12):4313-21. (Abstract)		
	C35	HYMOWITZ SG, et al., "A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL." Biochemistry. 2000 Feb 1;39(4):633-40.		
	C36	HYMOWITZ SG, et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5." Mol Cell. 1999 Oct;4(4):563-71.		
	C37	IGAKI T, et al., "Eiger, a TNF superfamily ligand that triggers the Drosophila JNK pathway." EMBO J. 2002 Jun 17;21(12):3009-18.		
	C38	JAKUBOWSKI A, et al., "Dual role for TWEAK in angiogenic regulation." J Cell Sci. 2002 Jan 15;115(Pt 2):267-74.		
	C39	JO M, et al., "Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand." Nat Med. 2000 May;6(5):564-7.		
	C40	JUNG G, et al., "Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments." Cancer Res. 2001 Mar 1;61(5):1846-8.		
	C41	KANDA H, et al., "Wengen, a member of the Drosophila tumor necrosis factor receptor superfamily, is required for Eiger signaling." J Biol Chem. 2002 Aug 9;277(32):28372-5.		
	C42	KAPLAN MJ, et al., "TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages." J Immunol. 2000 Mar 15;164(6):2897-904.		
	C43	KARPUSAS M, et al., "Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes." J Mol Biol. 2002 Feb 1;315(5):1145-54.		
	C44	KELLY K, et al., "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death." Cancer Res. 2000 Feb 15;60(4):1021-7.		
	C45	KHARE SD, et al., "The role of TALL-1 and APRIL in immune regulation." Trends Immunol. 2001 Feb;22(2):61-3.		
	C46	KOJIMA T, et al., "TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles." J Biol Chem. 2000 Jul 7;275(27):20742-7.		
	C47	KUMAR A, et al., "The ectodermal dysplasia receptor activates the nuclear factor-kappaB, JNK, and cell death pathways and binds to ectodysplasin A." J Biol Chem. 2001 Jan 26;276(4):2668-77.		
	C48	KUNIASU Y, et al., "Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation." Int Immunol. 2000 Aug;12(8):1145-55.		
	C49	KWEON MN, et al., "CD40L in autoimmunity and mucosally induced tolerance." J Clin Invest. 2002 Jan;109(2):171-3.		
	C50	KWON B, et al., "Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand." J Biol Chem. 1999 Mar 5;274(10):6056-61.		
	C51	LANE P. "Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells." J. Exp Med. 2000 Jan 17;191(2):201-6.		
	C52	LAWRENCE D, et al., "Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions." Nat Med. 2001 Apr;7(4):383-5.		

Examiner Signature	Date Considered	4/6/2006
--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/611,399	
			Filing Date	July 1, 2003	
			First Named Inventor	DESJARLAIS et al.	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	5	of	8	Attorney Docket Number	A-71273-3/RMS/RMK

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>Ude</i>	C53	LITINSKIY MB, et al., "DCs induce CD40-independent immunoglobulin class switching through BLYS and APRIL." Nat Immunol. 2002 Sep;3(9):822-9.	
	C54	LIU Y, et al., "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands." Cell. 2002 Feb 8;108(3):383-94.	
	C55	LUTGENS E, et al., "CD40-CD40L interactions in atherosclerosis." Trends Cardiovasc Med. 2002 Jan;12(1):27-32.	
	C56	LYNCH CN, et al., "TWEAK induces angiogenesis and proliferation of endothelial cells." J Biol Chem. 1999 Mar 26;274(13):8455-9.	
	C57	MACKAY F, et al., "TNF ligands and receptors in autoimmunity: an update." Curr Opin Immunol. 2002 Dec;14(6):783-90.	
	C58	MACPHERSON AJ, et al., "BLYSful interactions between DCs and B cells." Nat Immunol. 2002 Sep;3(9):798-800.	
	C59	MAINI RN, et al., "Anti-cytokine therapy for rheumatoid arthritis." Annu Rev Med. 2000;51:207-29.	
	C60	MATSUI H, et al., "LIGHT, a member of the tumor necrosis factor ligand superfamily, prevents tumor necrosis factor-alpha-mediated human primary hepatocyte apoptosis, but not Fas-mediated apoptosis." J Biol Chem. 2002 Dec 20;277(51):50054-61.	
	C61	MCDONALD ER 3rd, et al., "Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling." J Biol Chem. 2001 May 4;276(18):14939-45.	
	C62	MCHUGH RS, et al., "CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor." Immunity. 2002 Feb;16(2):311-23. (Abstract)	
	C63	MITSIADIS N, et al., "Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases." Trends Endocrinol Metab. 2001 Nov;12(9):384-90.	
	C64	MONGKOLSAPAYA J, et al. "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation." Nat Struct Biol. 1999 Nov;6(11):1048-53.	
	C65	MOORE PA, et al., "BLYS: member of the tumor necrosis factor family and B lymphocyte stimulator." Science. 1999 Jul 9;285(5425):260-3.	
	C66	MORENO E, et al., "Evolution of TNF signaling mechanisms: JNK-dependent apoptosis triggered by Elger, the Drosophila homolog of the TNF superfamily." Curr Biol. 2002 Jul 23;12(14):1263-8.	
	C67	MURATA K, et al., "Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand." J Exp Med. 2000 Jan 17;191(2):365-74.	
	C68	NAGATA S. "Steering anti-cancer drugs away from the TRAIL." Nat Med. 2000 May;6(5):502-3.	
	C69	NAKAYAMA M, et al., "Multiple pathways of TWEAK-induced cell death." J Immunol. 2002 Jan 15;168(2):734-43.	
	C70	NEPOM GT. "Therapy of autoimmune diseases: clinical trials and new biologics." Curr Opin Immunol. 2002 Dec;14(6):812-5.	
	C71	NOCENTINI G, et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis." Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6216-21.	
<i>✓</i>	C72	NOHARA C, et al., "Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells." J Immunol. 2001 Feb 1;166(3):2108-15.	

Examiner Signature <i>Gregory Frank</i>	Date Considered	4/6/2006
---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/611,399	
			Filing Date	July 1, 2003	
			First Named Inventor	DESJARLAIS et al.	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	6	of	8	Attorney Docket Number	A-71273-3/RMS/RMK

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>4</sup>
LMH	C73	OREN DA, et al., "Structural basis of BLYS receptor recognition." Nat Struct Biol. 2002 Apr;9(4):288-92.	
	C74	PARRY TJ, et al., "Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLYS) in mice." J Pharmacol Exp Ther. 2001 Feb;296(2):396-404.	
	C75	PENGUE G, et al., "Functional characterization of the promoter of the X-linked ectodermal dysplasia gene." J Biol Chem. 1999 Sep 10;274(37):26477-84.	
	C76	QIN J, "Av+oiding premature apoptosis of normal epidermal cells." Nat Med. 2001 Apr;7(4):385-6.	
	C77	RENNERT P, et al, "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth." J Exp Med. 2000 Dec 4;192(11):1677-84.	
	C78	RICCARDI C, et al., "Glucocorticoid hormone-induced modulation of gene expression and regulation of T-cell death: role of GITR and GILZ, two dexamethasone-induced genes." Cell Death Differ. 1999 Dec;6(12):1182-9. (Abstract)	
	C79	RONCHETTI S, et al., "Role of GITR in activation response of T lymphocytes." Blood. 2002 Jul 1;100(1):350-2. (Abstract)	
	C80	ROONEY IA, et al., "The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells." J Biol Chem. 2000 May 12;275(19):14307-15.	
	C81	ROSCHKE V, et al., "BLYS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases." J Immunol. 2002 Oct 15;169(8):4314-21.	
	C82	SACCO MG, et al., "Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome." Cancer Gene Ther. 2000 Oct;7(10):1299-306.	
	C83	SCHEU S, et al., "Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis." J Exp Med. 2002 Jun 17;195(12):1613-24.	
	C84	SCHNEIDER P, et al., "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth." J Exp Med. 1999 Jun 7;189(11):1747-56.	
	C85	SCHNEIDER P, et al., "Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A." J Biol Chem. 2001 Jun 1;276(22):18819-27.	
	C86	SCHONBECK U, et al., "CD40 signaling and plaque instability." Circ Res. 2001 Dec 7;89(12):1092-103.	
	C87	SHARMA K, et al., "Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000 Dec;88(3):333-47.	
	C88	SHIMIZU J, et al., "Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance." Nat Immunol. 2002 Feb;3(2):135-42.	
	C89	SHIN HH, et al., "Recombinant glucocorticoid induced tumor necrosis factor receptor (rGITR) induces NOS in murine macrophage." FEBS Lett. 2002 Mar 13;514(2-3):275-80.	
	C90	SHU HB, et al., "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1." Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9156-61.	
	C91	SRIVASTAVA RK. "Intracellular mechanisms of TRAIL and its role in cancer therapy." Mol Cell Biol Res Commun. 2000 Aug;4(2):67-75.	
	C92	SRIVASTAVA RK. "TRAIL/Apo-2L: mechanisms and clinical applications in cancer." Neoplasia. 2001 Nov-Dec;3(6):535-46.	
	C93	STEIN JV, et al., "APRIL modulates B and T cell immunity." J Clin Invest. 2002 Jun;109(12):1587-98.	

Examiner Signature	<i>Gregory A. Kunkel</i>	Date Considered	4/6/2006
--------------------	--------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/611,399	
			Filing Date	July 1, 2003	
			First Named Inventor	DESJARLAIS et al.	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	7	of	8	Attorney Docket Number	A-71273-3/RMS/RMK

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
[Signature]	C94	SUDA T, et al., "Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing." J Exp Med. 1997 Dec 15;186(12):2045-50.		
	C95	SUDA T, et al., "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families." Endocr Rev. 1999 Jun;20(3):345-57.		
	C96	TAKAHASHI N, et al., "A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANSE/RANKL, regulates osteoclast differentiation and function." Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55.		
	C97	TAKAYANAGI H, et al., "RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta." Nature. 2002 Apr 18;416(6882):744-9.		
	C98	TAMADA K, et al., "Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease." J Clin Invest. 2002 Feb;109(4):549-57.		
	C99	TAMADA K, et al., "Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT." J Immunol. 2002 May 15;168(10):4832-5.		
	C100	TAMADA K, et al., "Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway." Nat Med. 2000 Mar;6(3):283-9.		
	C101	TAN J, et al., "CD40-CD40L interaction in Alzheimer's disease." Curr Opin Pharmacol. 2002 Aug;2(4):445-51.		
	C102	THEILL LE, et al., "RANK-L and RANK: T cells, bone loss, and mammalian evolution." Annu Rev Immunol. 2002;20:795-823.		
	C103	TOWN T, et al., "CD40 signaling and Alzheimer's disease pathogenesis." Neurochem Int. 2001 Nov-Dec;39(5-6):371-80.		
	C104	UGUREL S, et al., "Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients." Clin Cancer Res. 2001 May;7(5):1282-6.		
	C105	WAJANT H. "The Fas signaling pathway: more than a paradigm." Science. 2002 May 31;296(5573):1635-6.		
	C106	WALCZAK H, et al., "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo." Nat Med. 1999 Feb;5(2):157-63.		
[Signature]	C107	WANG H, et al., "TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice." Nat Immunol. 2001 Jul;2(7):632-7.		
	C108	WARE CF. "APRIL and BAFF connect autoimmunity and cancer." J Exp Med. 2000 Dec 4;192(11):F35-8.		
	C109	WEINBERG AD. "OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines." Trends Immunol. 2002 Feb;23(2):102-9.		
	C110	WHITESIDE TL. "Tumor-induced death of immune cells: its mechanisms and consequences." Semin Cancer Biol. 2002 Feb;12(1):43-50.		
	C111	WILEY SR, et al., "A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis." Immunity. 2001 Nov;15(5):837-46.		
	C112	WILLIAMS-ABBOTT L, et al., "The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand." J Biol Chem. 1997 Aug 1;272(31):19451-6.		
	C113	WU T, et al., "The effect of OX40/OX40L and CD27/CD70 pathways on allogeneic islet graft rejection." Transplant Proc. 2001 Feb-Mar;33(1-2):217-8.		

Examiner Signature	[Signature]	Date Considered	4/6/2006
--------------------	-------------	-----------------	----------



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

<p>Substitute for form 1449A/PTO (Modified)</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>			<b>Complete if Known</b>		
			Application Number	10/611,399	
			Filing Date	July 1, 2003	
			First Named Inventor	DESJARLAIS et al.	
			Art Unit	1646	
			Examiner Name	To Be Assigned	
Sheet	8	of	8	Attorney Docket Number	A-71273-3/RMS/RMK

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C114	YAN M, et al., "Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors." Science. 2000 Oct 20;290(5491):523-7.		
	C115	YE Q, et al., "Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival." J Exp Med. 2002 Mar 18;195(6):795-800.		
	C116	YIN D, et al., "Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy." Transplantation. 2002 Aug 15;74(3):345-54.		
	C117	YU G, et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity." Nat Immunol. 2000 Sep;1(3):252-6.		
	C118	ZHAI Y, et al. "VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo." FASEB J. 1999 Jan;13(1):181-9.		
	C119	ZHANG J, et al., "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus." J Immunol. 2001 Jan 1;166(1):6-10.		

Examiner Signature		Date Considered	4/6/2006
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2